Method of treating patients with acne vulgaris and connective tissue dysplasia
SUBSTANCE: method involves administering Aevit, Unidox as a background therapy of degree I and II, and Isotretinoin and Cynovit gel as a background therapy of degree III and IV. Besides, Magnerot® 3.0 g is taken once a day (1.0 g three times a day) throughout the all background therapy.
EFFECT: invention enables providing higher clinical effectiveness in the patients with acne and connective tissue dysplasia.
1 tbl, 4 dwg
The invention relates to medicine, namely to dermatology and cosmetology.
The problem of acne is one of the most important in modern dermatology. Acne occurs in 85% of persons aged 12 to 25 years old, have a tendency to higher incidence of illness among patients of working age and an increase in the frequency of severe forms[1, 2, 3].
The high prevalence, high rate of complications and refractory forms of acne, frequent psycho-emotional manifestations of the disease make it a social problem of dermatology and cosmetology.
Acne is a polymorphic multifactorial chronic disease of the hair follicles and sebaceous glands, manifested by comedones and inflammatory lesions of the skin in the form of papules, pustules, nodes.
Numerous studies have shown that the causes of acne are varied. Have the value of nature and the properties of microorganisms in the lesions, the immune and neuroendocrine systems of the vascular wall skin[4, 5, 6].
However, some aspects of the pathogenesis of acne remain to date largely unexplored. In particular, have not been studied genetically-determined value of connective tissue dysplasia (CTD) is a syndrome manifested external stigmata of disambiguate in combination with dysfunction of internal organs, and its influence on the clinical form �knye and the effectiveness of treatment.
Connective tissue dysplasia includes more than 20 syndromes associated with dysplasia dependent changes and pathological conditions, reflected in the International classification of diseases X revision (ICD-X).
For many variants of undifferentiated CTD characteristic changes in the skin: the thinness, weakness, low elongation, thinning of the subcutaneous fat layer, petechiae, scars, keloid scars, multiple pigmented spots, etc. [7, 8].
During embryogenesis connective tissue (CT) is involved in the formation of hair follicles and sebaceous glands - the leading factors in the pathogenesis of acne .
Thus, a high incidence of PT in the human body in General, and including in the skin, its importance in embryogenesis and functioning of the structural components of the skin (hair follicles, sebaceous glands) suggests a possible relationship of the development of the DST and acne.
The task of determining the effect of DST on the development of acne and the development of a plan of treatment.
The task is achieved by the analysis of CTD in patients with acne further course of treatment, depending on the I-II degree, III-IV degree of acne, additionally Magnerot® at a dose of 3.0 g per day (1.0 g three times daily).
In accordance with the guidelines National guidelines for the diagnosis of hereditary disorders of PT analyze the phenotype is�die signs of connective tissue dysplasia. They are divided into main (hyperactivity skin, flat feet, disturbances of the organ of vision, dilatation, deformation of the spine and thorax) and secondary (anomalies of the ears, abnormal development and growth of the teeth, transient joint pain, dislocations and subluxations of the joints, arachnodactyly, slender fingers, etc.). Classification of the degree of DST: under the norm implies the absence or permits the presence of 1-2 signs; cervical dysplasia characterized by 3-5 signs; severe dysplasia 6 and more signs. Patients included in the study provided that they have at least 3 external stigmas of disambiguate in accordance with the diagnostic criteria of the DST .
Was studied 250 patients with different severity of acne (one HUNDRED), of which 175 acne with CTD. In accordance with modern approaches to the diagnosis of DST according to the analysis of external mortality from 175 115 patients (67.7 percent), there was a moderate degree of DST, 60 (34.3 percent) others - various dysplastic syndromes and phenotypes, including marfanoid habitus in 7 (11,7%), joint hypermobility syndrome - 4 (6,7%), unclassifiable phenotype - 49 (81,6%).
Table 1 depicts the classification of acne severity of lesions [10, 11].
A quantitative analysis of the frequency of occurrence of CTD among patients with RA�governmental options course acne has revealed a statistically significant differences (criteria for t-test, Mann-Whitney, Wilcoxon, Pearson) symptom severity of dysplasia for patients with mild, moderate and severe disease. So, the patients I HUNDRED on average revealed a 3.7±0.96 symptom of, II STA - 4,3±0,78, III HUNDRED - 4,8 ±0.45 and IV one HUNDRED and 5.4±1.57 symptom of DST. Differences in the frequency of occurrence of CTD between groups of variants of the course of acne is statistically significant (p<0,05).
Assessment of somatotype was performed in 175 patients with acne DST and a control group of 75 patients with acne.
Among 75 patients of acne (control group - 1) in 52% of patients were predominant component of mesomorphy. Component of endomorphin had 21.3% of persons, a component of ectomorphy - 20,0% . Not determined the predominance of the somatotype scores in 6.7% of patients.
The somatotypes acne patients in Association with DST differ from those in acne without DST, indicating the adverse effect of DST on the development of acne (p<0,05). From the point of view of the clinical manifestations of acne in conjunction with CTD can talk about the influence of somatotype on their variability. The most pronounced on the severity of the acne symptoms identified in patients with uncertain somatotype. So, somatotype of the patient even in the long course of the disease had no significant effect on acne. At the same time when DST up to equality somatotype was more often identified in patients with more severe acne p� than mesomorphic, but lighter than in patients with ectomorphic and unspecified type.
Examined 250 patients with acne who were divided into 3 groups. The core group (CG) included 100 patients with acne were combined with CTD; in the first control group of 75 patients with acne, a second control group of 75 persons who have acne combined with CTD.
76 acne patients with CTD and only 37 with acne determined the content of magnesium in blood plasma and erythrocytes using a diagnostic kit Cormey-Mg-250.
In patients with acne DST magnesium deficiency in plasma was detected in 39 (51.3%) of 76, in erythrocytes - 46 (56,6%). In patients of acne without DST indices were close to those of a healthy person (normal 0.7 to 1.1 µmol/l) is statistically significant difference between groups (p<0,05).
Therapy patients of I and II degree of acne include aevitum 1 caps. 2 times a day inside one month, one dose (Solutab®) 100 mg per day orally 6-8 weeks; externally recommended to wash the gel Zinovich evening 6-8 weeks, the night gel clinit once daily for 4 weeks
Therapy for patients with III-IV degree of acne were of isotretinoin (Roaccutane®) at the rate of 0.75 mg per kg of body weight once a day for 5-6 months and gel Zinovich once in the evening throughout the course of treatment.
The main group of patients (with acne DST) in addition to therapy (at any degree of acne) received �magnerot® (magnesium salt of orotic acid) at a dose of 3.0 g per day (1.0 g three times daily) throughout the course of treatment.
Magnesium is a trace element, which is part of over 300 enzymes in the body, participates in intra - and extracellular maturation of collagen and other structural elements of connective tissue. A deficiency of magnesium ions contributes to the development of the DST .
In the first control group with acne and in the second control group - acne with CTD, prescribed therapy, taking into account only the severity of acne (I-IV class).
For the purpose of studying the results of treatment of patients of acne developed criteria for its evaluation. Clinical recovery is considered the absence of clinical manifestations, the disappearance or significant decrease in the total number of inflammatory cells due to the regression of papules and/or pustules. Clinical improvement - signs of regression of the vast number of papules and/or pustules, even with a slight increase of the total number of inflammatory cells is not more than 10%. No changes - no changes of cutaneous manifestations; deterioration - increase the total number of inflammatory cells at the expense of papules and/or pustules more than 10%, no signs of regression of previous eruptions. "The positive result of the" treatment consider clinical recovery + clinical improvement.
In Fig. 1 shows the results of treatment of patients with OG supplementary prescribing the drug, Magnerot®. As can be seen from the figure,the clinical recovery occurred in 34% of persons clinical improvement - 49,0%, the result, no change was documented in 17.0% of patients.
Magnesium content determined in plasma and erythrocytes in patients with acne and DST before treatment, revealed a reliable decrease (p<0.05) in the months after the end of therapy with the appointment of Magnerot, had a tendency to normalization of the indicators close to those of a healthy person (normal is 0.7-1.1 mmol/l).
In a remote period, there were problems in 7.0% of patients of the main group, but to a lesser intensity than before therapy.
Patients had a long history of the disease and the number of external stigmas of disambiguate more than five. The somatotype patients belonged mostly to uncertain and ectomorphic and up to equality types.
In Fig. 2 presents the early results of treatment of patients with acne in the absence of connective tissue dysplasia. As can be seen from the figure, the clinical recovery was achieved in 48,0% of patients, clinical improvement is at 34.7 per cent, the result of treatment, no change - 17,3%.
Summary the effectiveness of therapy of patients in the second group (control acne with CTD), which Magnerot® advanced is not assigned to therapy is presented in Fig. 3.
As can be seen from the figure, the clinical recovery was observed in 33.3% of individuals, clinical improvement - 30,7%, results� treatment was no change in 26.7% of patients and 9.3 per cent occurred in the course of therapy.
In Fig. 4 presents a comparison of immediate results of treatment of patients in three groups according to the "positive results" (clinical recovery + clinical improvement). As can be seen from figure 4, the proposed method of treatment is with the connection of the drug Magnerot® - the core group appointed by acne patients with CTD, were close in positive outcomes for persons who had only acne - p<0,05 (first control group) and exceeded the effectiveness of therapy in the group with acne DST 19.0% - p<0,05 (second control group) who were not appointed Magnerot®.
The proposed scheme of treatment of acne patients with connective tissue dysplasia, depending on the degree of acne (I-IV) and the appointment of the drug Magnerot®, allows to increase the effectiveness of therapy in persons of this category 19.0%.
Sources of information
1. Arabian E. A. Modern view of the treatment of acne: status challenges and new opportunities / E. A. Arabian // Attending physician. - 2003. - No. 4. - S. 20-25.
2. Monakhov S. A. psycho-Emotional disorders in patients suffering from acne / S. A. Monks, A. L. Ivanov, M. A. Samgin // ROS. Journal of skin and generic. diseases. - 2003. - No. 4. - S. 45-52.
3. Cargnello A. Acne: what's new? / A. Cargnello // MJA. - 1996. - Vol. 165. - P. 153-158.
4. Adaskevich V. P. Acne vulgaris and pink / VP adaskevich. - M.: Medical book, N. Novgorod the ngma, 2003. - 160 p.
5. Males A.V. Acne and AK�ifornia dermatoses / V. A. Males // M., 2009. - 288 p.
6. Goodmann G. Acne. Natural history, facts and myths / G. Goodmann // Aust. Fam. Physician. - 2006. - Vol. 35. - No. 9. - P. 613-616.
7. Nechaev G. I. connective tissue Dysplasia: terminology, diagnosis, clinical management of patients / G. I. Nechaeva, I. A. V. // Omsk. - 2007. - 188 S.
8. Heath B. Modern methods of somatotyping. Modernized method of determining somatotype / B. Heath, J. E. Carter // Questions of anthropology. - M., 1969. - Vol. 33 - 19 C.
9. Cerides G. S. Histopathology and clinical characteristics of dermatoses / G. S. Cerides, V. P. Fedotov, A. D. Dudun, V. A. Tumansky // 1st ed. - D., 2004. - P. 11-67.
10. Acne (ed Kubanova A. A.). - M.: DEX, 2010. - 28 S. - (Clinical guidelines) Russian society of dermatovenerologists.
11. Consensus on Acne Classification / AAD, 2006.
12. Nechaev G. I. Efficacy of magnesium in patients with connective tissue dysplasia / G. N. Nechaev, S. M. Yudin, O. V. Tikhanova // Aktual. Vopr. internal pathology. Connective tissue dysplasia. - Omsk. - 2005. - S. 209-214.
Method of treatment of patients with acne vulgaris (acne) with dysplasia of connective tissue, including the acceptance of Evita, one dose in the treatment of I and II degree of acne and the intake of isotretinoin and gel Zinovia in the treatment of III and IV degree of acne, characterized by one time per day 3.0 g Magnerot® (1.0 g three times daily) throughout the course of basic therapy.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutics. Gel form of azelaic acid is described. Gel form includes micronized azelaic acid and additional substances: benzoic acid, disodium edetate, carbomer Carbopol 980, propylene glycol, sodium hydroxide, glycoceramides purified, isopropylmiristate, polysorbate 20, purified water.
EFFECT: invention is provided by obtaining stable medication in form of gel, which does not produce local irritating action in case of long-term on-skin applications.
11 cl, 15 dwg, 5 tbl
SUBSTANCE: method involves administering an anthelminthic agent in the period of stationary process stage; the anthelminthic treatment is preceded by administering chophytol 200 mg 3 times a day before meals for 14 days; the anthelminthic treatment involves administering Osinol food supplement 2 tablets 3 times a day during meals for 14 days; thereafter, chophytol is taken in a dose of 200 mg 3 times a day before meals for 14 days; 7 days later, the repeated course of the anthelminthic treatment with Osinol food supplement 2 tablets 3 times a day during meals is prescribed to be administered for 14 days; the entire therapeutic course involves washing the face with the Setaphyldermocontrol foaming facial cleanser 2 times a day followed by applying an SPF30 product on the face once after the morning wash.
EFFECT: reducing the number of complications and the high efficacy of the anthelminthic treatment.
SUBSTANCE: praziquantel is administered in a single dose of 20 mc/kg for the first day of treatment in the daytime, and withdrawn; on the following day, the conducted therapy is added with introducing Gelmicide, a biologically active food supplement, in a dose of 2 capsules with meals for 21 days; the course is repeated 10 days later in a dose of 2 capsules 2 times a day with meals for 14 days.
EFFECT: reducing the rate of complications and increasing the high dishelminthisation efficacy.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of pharmaceutics, namely, deals with compounds of formula , suitable for reduction of regulation of biological activity of melanocortin-5 receptor (MC5R). Such diseases and/or conditions include, but are not limited by, acne, seborrhoea, seborrheic dermatitis, cancer and inflammatory diseases.
EFFECT: compounds of claimed invention can be applied for treatment of diseases and/or conditions, in which reducing regulation of MC5R is favourable.
3 cl, 109 ex, 7 tbl
SUBSTANCE: invention relates to a compound of formula (I) : or a salt thereof, wherein R1 and R5 are independently selected from H, OH and alkoxy; R2-R4 and R6-R8 are independently selected from H, OH, F, Cl, Br and I; R9 and R10 are C2-C8 alkenyl; under the condition that at least one of R1, R5 and R7 is OH or alkoxy; at least one of R2-R4, R6 and R8 is F, Cl, Br or I; and R2 and R6 are Cl. The invention also relates to an antibacterial composition and treatment methods.
EFFECT: improved properties.
18 cl, 7 ex, 10 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, and represents a pharmaceutical composition in the form of gel, which contains clindamycin phosphate, a combination of gel-forming polymer and hydrophilic dispersion phase, pH control agent, allantoin and lauryliminodipropionate sodium tocopheryl phosphate; the ingredients of the composition are taken in certain ratio, in g per 100 g.
EFFECT: invention provides the high level of antibacterial activity and stability.
5 cl, 1 tbl
SUBSTANCE: present group of inventions refers to medicine, namely to dermatology, and concerns treating telangiectasia or related symptoms. To this effect, an involved skin area is coated with a composition containing from approximately 0.4 wt % to approximately 0.6 wt % brimonidine providing its blood serum or plasma concentration, Cmax of approximately 54±28 pg/ml or less and AUC0-24h of approximately 568±277 pg·h/ml or less.
EFFECT: method provides the effective treatment of telangiectasia or related symptoms with no side local and systemic effects.
20 cl, 6 dwg, 6 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for treating acne, rosacea and hyperpigmentation, in the form of a gel which contains anchoic acid, a hydrophobic ingredient, a non-aqueous solvent, an emulsifying agent, a gel-forming polymer, a preserving agent, a pH control agent and additionally methylpyrrolidone with anchoic acid having a particle size of less than 100 mcm, while anchoic acid is related to methylpyrrolidone as 1:0.025 to 1:4.
EFFECT: invention provides easy penetration of anchoic acid through a horny layer and its resolution into the oil grand ducts and between skin cells, providing high concentration of anchoic acid that promotes better antibacterial, keratolytic and de-pigmentation effects.
5 cl, 2 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to a compound of Formula
where Y represents a group of formula -(CR9R10)-; X is selected from the group, consisting of -C(=O)-, -OC(=O)-, -NHC(=O)-, -(CR11R12)- and -S(-O)2-; Z represents a group of formula -(CR13R14)q-; R1 is selected from the group, consisting of C1-C12alkyl, optionally substituted with one substituent, selected from naphthyl, indole and biphenyl; C2-C12alkenyl, substituted with a substituent, selected from thienyl, naphthyl and phenyl, with the said phenyl being optionally substituted with 1-2 substituents; selected from halogen, trifluoroalkyl, C1-C6alkyl, methoxy and hydroxy; C3-C6cycloalkyl; C6-C10aryl, optionally substituted with 1-2 substituents, selected from halogen, phenyl, amino, phenoxy, C1-C6alkyl, methoxy, hydroxyl and carboxy; and C4-C9heteroaryl, selected from indole, quinoline, quinoxaline, benzofuranyl, benzothiophene, benzimidazole, benzotriazole, benzodioxin, benzothiasole, pyrazole, furyl and isoxazole, optionally substituted with a substituent, selected from C1-C6alkyl and phenyl; R2 and R3 each is independently selected from the group, consisting of H and C1-C12alkyl; R4a is selected from the group, consisting of H, C1-C12alkyl, optionally substituted with phenyl; C2-C12alkenyl, C3-C6cycloalkyl, C6aryl, C(=O)R15, C(=O)NR15R16, C(=O)OR15, SO2R15 and -C(=NR15)-NR16R17; R4d represents hydrogen or R4a and R4b, taken together with a nitrogen atom, which they are bound to, form an optionally substituted heterocyclic fragment, selected from piperidine, morpholine, pyrrolidine and azetidine, where the substituent is selected from C1-C12alkyl, hydroxy, halogen, carboxy and oxo; each R5a and R5b represents H, or R6, R7 and R8 each is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6-C10aryl, optionally substituted with halogen, or taken together with a carbon atom, which they are bound to, two or more of R6, R7 and R8 form a fragment, selected from the group, consisting of C2-C12alkenyl; C3-C6cycloalkyl, optionally substituted with C1-C6alkyl; C6aryl, optionally substituted with 2 substituents, selected from halogen; each R9 and R10 represents H or C1-C12alkyl, substituted with naphthyl; each R11 and R12 represents H; R13 and R14 represent H, or each R15, R16 and R17 is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6aryl, substituted with one substituent, selected from C1-C6alkyl; and C5-heteroaryl, additionally containing one nitrogen atom, with the said heteroaryl representing pyridyl; q represents an integer number, selected from the group, consisting of 2, 3 and 4; r represents 1; or its pharmaceutically acceptable salt. The invention also relates to particular compounds of 1,4-diazepan-2-one derivatives.
EFFECT: obtaining 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists.
21 cl, 7 tbl, 110 ex
SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used for selecting a therapeutic approach to acne in females by examining biological fluids and prescribing preparations depending on the clinical findings. The biological fluids are blood and urine; blood serum hormones and steroid urine profile are tested, and the derived values are compared to the standard norms specific for the absence of acne, while the preparations are prescribed according to the comparison results. Specifically, if observing an increase of blood luteinising hormone up to 16 mIU/ml, testosterone up to 4 ng/ml, an increase of urine androsterone up to 20 mcmole/24 hours, etiocholanolone up to 11 mcmole/24 hours, total 17-ketosteroids up to 35 mcmole/24 hours, van de Calseyde's discriminant up to 3, the combined oral contraceptive Jess with the anti-androgenic effect. If also observing an increase of immunoreactive protein up to 12.90 mcUnit/ml and insulin-line growth factor 1 up to 361.04 ng/ml, the combined oral contraceptive Jess and Metformine or Metformine are prescribed. If observing a decrease of blood oestradiol up to 140 pmole/l or an increase of the concentration of luteinising hormone up to 7 mIU/ml, dihydroepiandrosterone sulphate up to 4 mmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and testosterone up to 4 nmole/l in blood and an increase of urine androsterone up to 17 mcmole/24 hours, etiocholanolone up to 17 mcmole/24 hours, 11 - ketoandrosterone up to 2.5 mcmole/24 hours, 11 - ketoetiocholanolone up to 2.5 mcmole/24 hours, 17 - ketosteroids up to 50 mcmole/24 hours and van de Calseyde's discriminant up to 3, the glucocorticoid Metypred is prescribed. The high blood concentration of luteinising hormone up to 15 mIU/ml, dihydroepiandrosterone sulphate up to 6.82 mcmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and an increase of urine androsterone up to 19.5 mcmole/24 hours, etiocholanolone up to 16 mcmole/24 hours, dihydroepiandrosterone up to 7 mcmole/24 hours, 17 - ketosteroids up to 45 mcmole/24 hours and van de Calseyde's discriminant up to 3.5 enables using the combined oral contraceptive Jess and the glucocorticoid Metypred. And the preparation Dostinex is prescribed in observing the above values in a combination with an increase of blood prolactin up to 750 IU/ml and a decrease of blood oestradiol up to 95.48 pcg/ml.
EFFECT: method enables providing higher therapeutic selectivity and clinical effectiveness in acne without the need of thorough examination to be conducted.
SUBSTANCE: to determine density of otospongiosis focuses computer tomography of temporal bones with densitometry is carried out. Treatment duration is determined on the basis of obtained values of density. If density of otospongiosis focuses is less than 300 units HU, 4 courses of complex inactivating therapy are carried out. If density is 300-600 HU units -2 courses, if density is 600-900 units HU - 1 course. Duration of one course constitutes 3 months. During a year not more than two courses of therapy are carried out. Course of inactivating complex therapy includes intake of the following medications: bisphosphonates, sodium fluoride, calcium carbonate and vitamin D3. As bisphosphonates medication Bonviva is applied.
EFFECT: method makes it possible to increase efficiency of inactivating therapy in patients with different forms of active otosclerosis due to differential approach in selection of individual duration of carried out therapy.
SUBSTANCE: invention relates to agriculture, in particular to the poultry industry and can be used for growing broilers at the poultry farms as well in private or farm enterprises. The invention provides a method of prevention of mycotoxicosis in growing broilers, which is characterised in that it comprises adding to the main ration of the feed additive - adsorbent of white slurry obtained by neutralization of the slurry with sulphuric acid to pH 6-7, which is given to broilers during the entire growing period at the doses: from the 1st to the 7th day of feeding - 2 kg per ton of combined feed, from the 8th to the 14th day - 4 kg per ton of combined feed, and from the 15th to 38th day - 6 kg per ton of combined feed.
EFFECT: invention enables to improve the productivity of the poultry.
2 dwg, 11 tbl
SUBSTANCE: described is a method of obtaining a composite chitosan-based material, which contains aspartic or glutamine amino acids in a quantity from 2 to 5 wt %, as well as calcium phosphates with a ratio of Ca/P from 1.0 to 1.67. The method consists in barbotage through a suspension of calcium phosphates, obtained in situ in a solution of chitosan and aspartic or glutamic acid, with the following lyophilic drying of the foamed products. Porous matrices can be applied in dentistry, maxillofacial surgery, osteoplastic surgery as implants in the treatment of bone tissue defects.
EFFECT: obtained samples are characterised by a uniform porous structure with the simultaneous reduction of calcium phosphate dimensions to a nano-level with the reduction of the number of material obtaining operations.
2 dwg, 5 ex
SUBSTANCE: invention represents an agent for treating a pulp inflammation differing by the fact that it contains Bezornil ointment and Dycal ivory paste in ratio 1:1 blended until smooth.
EFFECT: invention provides relieving oedema and pain on the day of doctor's appointment, accelerating the pulp tissue regeneration process, creating the reparative dentin within 30 days, and ensures the higher clinical effectiveness in the pulp inflammations.
2 ex, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for producing a complex compound of dihydroquercetin with metal ions specified in zinc, copper (II) or calcium possessing antioxidant activity. A method consists in the fact that dihydroquercetin and metal salt is mixed in the dry state in a reactor in certain molar ratio; that is followed by adding water at a certain temperature or ethanol or aqueous-alcoholic solution at a room temperature at the controlled medium acidity; using metal salts containing weak acid anions provides medium pH equal to 5.0-5.6; using the metal salts containing strong acid anions requires reducing pH to 7 by adding an alkaline solution; the reaction is completed almost immediately for the first 5 minutes; the precipitation is filtered in water and/or ethanol; dried in air, then in a drying box to constant weight, and a complex compound is produced. The declared method enables reducing the production costs substantially and cheapening the technological process in achieving the target yield with the preset properties.
EFFECT: method enables producing the stable metal structures and individual powdered substances.
3 cl, 3 dwg, 3 tbl, 12 ex
SUBSTANCE: described is a method of bone tissue substitution, in which as a bone-substituting material applied is a biodegradable material of the following composition, wt %: biological hydroxyapatite - 50-52, magnesium phosphate - 30-32, calcium hydrophosphate - 8-10, calcium hydroxide - 4.8-5.3, sodium alginate - the remaining part. As a binding agent applied is casein in the form of an ammonia solution with the ratio of powder mass of the biodegradable material to the ammonia casein solution of 1:1-1.5.
EFFECT: reduction of terms and improvement of surgical operation results.
4 dwg, 2 tbl, 2 ex
SUBSTANCE: invention refers to medicine, namely to orthopaedics, and can be used for correcting the bone tissue status and preventing fractures in cardiovascular patients. That is ensured by administering Calcemin advance 1 tablet 1-3 times a day with meals for 6 months.
EFFECT: method enables preventing fractures by increasing bone mineral density (BMD) with reducing neurological symptoms that reduces a risk of patients' fall-downs.
1 tbl, 4 dwg, 2 ex
SUBSTANCE: for patient with alimentary obesity preliminarily determined are: clearance of osmotically free water (CFW) and colloid oncotic pressure (COP). If CFW level is lower than -0.45 ml/min and COP is lower than 18 mm Hg, therapy starts from intravenous introduction of 6% HES "Voluven" in dose 6.5 ml/kg/day at rate 350 ml/h. Immediately after the end of infusion introduction with syringe doser of 25% solution of magnesium sulphate in dose 0.75 ml/kg/day at rate 2.8 ml/h. For patient without obesity, if CFW level is lower than -0.6 ml/min and COP is lower than 21 mm Hg, therapy is started from intravenous introduction of 6% HES "Voluven" in dose 5.5 ml/kg/day at rate 300 ml/h. 25% solution of magnesium sulphate in dose 0.9 ml/kg/day at rate 2.4 ml/h is also introduced by means of syringe doser. Treatment is carried out during a day.
EFFECT: carrying out adequate therapy in said category of patients due to selection of mode of introduction of preparations, conditioning fast recovery of kidney function.
2 cl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with a crystalloid cardioplegic solution, which contains salt solution, including sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium hydrogen carbonate, water for injections and a structural analogue of natural apelin X-Arg(NGY)-Pro-Arg-Leu-Ser-His-Lys-Cly-Pro-Nle-Pro-Phe-Z, where X=CH3, Y=H, Z=OH. The group of inventions also deals with the crystalloid cardioplegic solution, containing salt solution, including sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium hydrogen carbonate, water for injections and structural analogue of natural apelin X-Arg(NGY)-Pro-Arg-Leu-Ser-His-Lys-Cly-Pro-Nle-Pro-Phe-Z, where X=H, Y=NO2, Z=NH2.
EFFECT: group of inventions provides the recovery of the coronary flow, cardiac contractile and pump function in case of the reperfusion and the reduction of injury to membranes of cardiomyocytes.
2 cl, 2 dwg, 8 tbl, 4 ex
SUBSTANCE: invention relates to medicine, in particular to application of medication "Osteomed" for treating arthritis and arthrosis.
EFFECT: said application makes it possible to accelerate treatment of arthritis and arthrosis, increased efficiency of such treatment with simultaneous elimination of risk of hypercalcemic condition development.
SUBSTANCE: invention refers to medicine and describes a method for producing glucosamine sulphate nanocapsules by non-solvent addition, wherein glucosamine sulphate is added in small amounts to a carrageenan suspension used as a nanocapsule shell in butanol, containing E472c preparation 0.01 g as a surfactant; the produced mixture is agitated and added with the non-solvent hexane 6 ml, filtered, washed in hexane and dried.
EFFECT: invention provides simplifying and accelerating the process of nanoencapsulation in carrageenan and higher weight yield.